Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 that is in Phase 1/2a clinical trial for the treatment of patients with solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
Metrics to compare | IMRX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIMRXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −4.9x | −4.3x | −0.6x | |
PEG Ratio | −0.45 | 0.07 | 0.00 | |
Price/Book | 1.3x | 4.6x | 2.6x | |
Price / LTM Sales | - | 22.5x | 3.4x | |
Upside (Analyst Target) | 201.7% | 48.9% | 41.3% | |
Fair Value Upside | Unlock | 2.1% | 4.9% | Unlock |